|
|
Control group
(n = 18) |
Aclang group
(n = 35) |
P-value |
Age (years) |
|
63.2 ± 9.5 |
62.5 ± 9.0 |
0.749 |
Sex |
Female/Male |
8/10 |
14/21 |
0.756 |
Biliary decompression |
No/Yes |
12/6 |
20/15 |
0.502 |
Tumor Location |
Head/ Body+Tail |
11/7 |
23/12 |
0.590 |
Resectability1 |
PR/BR/LA |
14/4/0 |
23/11/1 |
0.602 |
Operation |
PD/ DPS/TP |
10(8)*/7/1 |
23(21)*/12/0 |
0.392 |
Vascular resection2 |
No/Yes |
16/1 |
29/6 |
0.576 |
Blood loss (ml) |
|
709.4 ± 556.9 |
660.2 ± 423.1 |
0.667 |
Transfusion |
No/ Yes |
12/5 |
25/10 |
0.726 |
Operation time (min) |
No/ Yes |
423.3 ± 192.2 |
426.0 ± 171.9 |
0.843 |
Tumor Size (cm) |
|
2.7 ± 1.8 |
2.9 ± 1.3 |
0.585 |
T-stage |
T1/T2/T3/T4 |
0/0/17/0 |
1/1/31/2 |
0.510 |
N-stage |
N0/N1 |
7/10 |
13/22 |
0.964 |
PNI |
No/ Yes |
6/11 |
11/23 |
0.781 |
LVI |
No/ Yes |
12/5 |
19/15 |
0.655 |
Tumor Grade |
Well |
6 |
5 |
0.466 |
|
Moderate |
11 |
26 |
|
|
Poor |
1 |
3 |
|
|
Undifferentiated |
0 |
1 |
|
R0 resection |
R0/R1/R2 |
15/2/0 |
29/3/3 |
0.590 |
Postoperative chemotherapy |
GEM-based/
5FU-based |
11/7 |
28/7 |
0.198 |
LOH (days) |
|
22.6 ± 12.1 |
19.9 ± 9.7 |
0.553 |
POPF |
No/ Yes |
15/2 |
34/1 |
0.915 |
Mortality |
No/ Yes |
17/0 |
35/0 |
NA |
12010 NCCN guidelines, PR=potentially resectable, BR=borderline resectable, LA=locally advanced
2Portal vein wedge resection (1) in the control group vs. portal vein segmental resection, (2) wedge resection, or (3) in the Aclang group. * ; indicates pylorus-preserving
procedure. PNI; perineural invasion, LVI; lymphovascular invasion, LOH; length of hospital stay, POPF; postoperative pancreatic fistula |